Table 2.
Main Perinatal Outcomes of the Study Population Stratified by the Presence of Preeclampsia at the Time of Demonstration of sFlt‐1/PlGF >655
| Perinatal Outcome | Total (N=237) | Preeclampsia at Inclusion | ||
|---|---|---|---|---|
| No (n=52) | Yes (n=185) | P Value | ||
| GA at diagnosis, median (Q1–Q3) | 29.0 (3.3) | 27.7 (25.6–30.4) | 29.4 (27.1–31.9) | <0.01 |
| GA at delivery, median (Q1–Q3) | 29.8 (3.3) | 28.9 (27.1–31.5) | 30.1 (27.8–32.5) | 0.03 |
| Time to delivery, median (IQR) | 4 (2–10) | 7 (4–13) | 4 (1–6) | <0.01 |
| sFlt‐1/PlGF, median (IQR) | 823 (718–1051) | 818 (725–1064) | 823 (712–1048) | 0.92 |
| Mean arterial pressure, mm Hg | 110±13 | 101±9 | 112±12 | <0.01 |
| Hypertension (SBP ≥140 or DBP >90 mm Hg) | 195 (78.1) | 10 (19.5) | 185 (100) | <0.01 |
| Reason for delivery | ||||
| Spontaneous onset | 1 (0.4) | 0 (0) | 1 (0.5) | |
| PPROM | 2 (0.8) | 1 (1.9) | 1 (0.5) | |
| Maternal indication due to preeclampsia | 105 (44.4) | 11 (21.2) | 94 (50.8) | <0.01 |
| Fetal indication due to FGR | 108 (45.4) | 31 (59.6) | 77 (41.6) | |
| Abruptio placentae | 15 (6.3) | 6 (11.5) | 9 (4.8) | |
| Other | 6 (2.5) | 3 (5.8) | 3 (1.6) | |
| Intrauterine demise | 21 (8.9) | 10 (19.2) | 11 (6.9) | <0.01 |
| Neonatal mortality | 15 (6.3) | 5 (9.6) | 10 (5.4) | 0.28 |
| Overall perinatal mortality | 36 (15.2) | 15 (28.8) | 21 (11.4) | <0.01 |
| Neonatal weight | 1024±445 | 828±438 | 1079±432 | <0.01 |
| NICU admission | 193 (81.4) | 39 (75.0) | 154 (83.2) | 0.27 |
| Days at NICU | 37.6±29.2 | 47.8±32.8 | 36.1±28.2 | 0.21 |
| Neonatal severe morbiditya | ||||
| Any | 74 (34.3) | 18 (42.9) | 56 (32.2) | 0.19 |
| Sepsis | 47 (21.8) | 13 (31.0) | 34 (19.5) | 0.11 |
| Bronchopulmonary dysplasia | 32 (14.8) | 7 (16.7) | 25 (14.4) | 0.61 |
| Necrotizing enterocolitis | 11 (5.1) | 3 (7.1) | 8 (4.6) | 0.50 |
| Periventricular leukomalacia | 5 (2.3) | 1 (2.4) | 4 (2.3) | 0.97 |
| Retinopathy (stage III–V) | 12 (5.6) | 4 (9.5) | 8 (4.6) | 0.21 |
| IVH grade III or IV | 6 (2.8) | 1 (2.4) | 5 (2.9) | 0.86 |
| Maternal severe morbidity | ||||
| Any | 99 (41.8) | 19 (36.5) | 80 (43.2) | 0.39 |
| Severe hypertension | 39 (16.5) | 3 (5.8) | 36 (19.5) | 0.02 |
| HELLP syndrome | 28 (11.8) | 3 (5.8) | 25 (13.5) | 0.13 |
| Abruptio placentae | 27 (11.4) | 11 (21.2) | 16 (8.7) | 0.01 |
| Oliguria (<500 mL/24 h) | 15 (6.3) | 0 (0) | 15 (8.1) | 0.03 |
| Pulmonary edema | 7 (3.0) | 1 (1.9) | 6 (3.2) | 0.62 |
| IDC | 2 (0.8) | 0 (0) | 2 (1.1) | 0.45 |
| Eclampsia | 3 (1.3) | 0 (0) | 3 (1.6) | 0.36 |
| Myocardial infarction | 1 (0.4) | 1 (1.9) | 0 (0) | 0.06 |
Data are mean±SD or n (%), unless otherwise stated. DBP indicates diastolic blood pressure; FGR, fetal growth restriction; GA, gestational age; HELLP, hemolysis, elevated liver enzymes, and low platelet count; IDC, intravascular disseminated coagulopathy; IQR, interquartile range; IVH, intraventricular hemorrhage; NICU, neonatal intensive care unit; PlGF, placental growth factor; PPROM, preterm premature rupture of membranes; Q, quartile; SBP, systolic blood pressure; and sFlt‐1, soluble fms‐like tyrosine kinase 1.
a
Calculated among neonatal survivors.